Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — H1 2026 Earnings Presentation
31 slides from Ekf Diagnostics's earnings presentation, Sep 15, 2026
Slide 1: EKF Interim Results 2026
EKF Interim Results 2026 Presented by Gavin Jones & Helen Jones 15th September 2026 ekfdiagnostics.com MRK-PRES-E-2025-004-EN
Slide 2: EKF
EKF Point-of-Care EKF manufactures point-of-care in vitro diagnostic devices and tests that deliver rapid, accurate results. Our solutions, distributed through a global network of partners, support healthcare professionals in making timely, informed decisions at or near the patient. Life Sciences EK
Slide 3: Presenters
Gavin Jones is Chief Executive Officer of EKF, appointed in Helen Jones is Chief Financial Officer of EKF, appointed in April March 2025. Formerly Chief Product Officer, he has driven 2026, bringing over 20 years of leadership in finance, product innovation, regulatory excellence, and global operati
Slide 4: Agenda
Agenda 01 H1 2026 Highlights 02 Five-Year Strategy 03 Commercial and Operational progress 04 Financial Update 05 Summary 4
Slide 5: H1 2026 Highlights
H1 2026 Highlights Financial Commercial & Operational Strategic Solid H1 performance in line with Point-of-Care strong order book in Focused on delivery of Five-year expectations H2 plan ▪ Revenue £25.0m, flat like-for-like ▪ Point-of-Care £15.0m, down 3% ▪ β-HB growth continued, up 4% in (H1 2025:
Slide 6: Revenue by Division
Revenue by Division Point-of-Care H1 2026 H1 2025 LFL* £15.0m H1 2026 vs £15.4m H1 2025* Timing – Key initiatives / tender closures 18,000 moved order deliveries into H2 ▼ -3% 15,000 Production – Challenges in H1 delayed lactate deliveries, resolved and on track for H2 12,000 ▲ +8% 9,000 Life Scienc
Slide 7: Revenue by Product/Portfolio
Revenue by Product/Portfolio H1 2026 H1 2025 Point-of-Care £15m 7.8 ▪ Hematology £7.8m: flat due to shift in tender deliveries Hematology PoC (-3%) in H2; excludes Egyptian volume now moved into H2. 8.0 ▪ Hemo Control remains the largest contributor, DiaSpect Tm a close second; HemataStat II up 5.5
Slide 8: Five-Year Strategy
Five-Year Strategy #1 Point-of-Care (PoC) #1 Ketone Testing (β- Transform EKF Life Hemoglobin HB) Laboratory & PoC Sciences into a CDMO • Deliver BCA contracts in • Continue to grow the β-HB • Rebrand Life Sciences US blood bank market LiquiColor® market share service offering 2026 Focus • Invest in
Slide 9: Commercial & Operational Progress
Commercial & Operational Progress Commercial Share of total β-HB revenue: ● A ● B ● C FY2023–FY2025 CAGR H1 2026 vs H1 2025 Hematology 3 US blood banks online with DiaSpect, 3 more coming +106% online in H2; ongoing negotiations with BCA members for 2027 onboarding +46% β-HB +8% Positive 106% gr
Slide 10: Introducing Nexus Bioworks
Introducing Nexus Bioworks A new identity and name to distinguish EKF’s Life Sciences services from EKF Diagnostics Point-of-Care portfolio — enabling a clearer service offering Distinct Identity Familiar Roots Convergence, Clarified New branding clearly separates EKF Life Deliberately distinct from
Slide 11: Scalable solutions from development to commercial manufacturing
Thank You Scalable solutions from development to commercial manufacturing • Nexus Bioworks has been supporting biotech, biopharma, and diagnostics clients in Thank You scaling microbial bioprocesses from early-stage development through to commercial manufacture for over 40 years. • Nexus Bioworks su
Slide 12: Outlook
Outlook Point-of-Care Growth With a full committed order book, significant tenders due to finalise, focus on blood banks, and production back up to full speed, the expectation is that Point-of-Care will bounce back into a growth position. Continued β-HB Growth By the end of 2026 β-HB is due to hit d
Slide 13: Financial Update
Thank You Financial Update ekfdiagnostics.com MRK-PRES-E-2025-004-EN
Slide 14: Financial Highlights
Financial Highlights ▪ Solif H1 performance - delivered on track ▪ Gross margin and AEBITDA both up - with a stronger H2 expected. ▪ Solid cash generation - impacted by higher US tax payments. ▪ Robust balance sheet - to continue to fund planned capex. ▪ Buybacks helping to drive EPS growth - EPS up
Slide 15: Solid financial performance
Solid financial performance £'000 H1 2026 H1 2025 Change Revenue 25,029 25,239 -0.8% Gross margin 53.0% Up from 50.2% on higher β-HB and consumable sales, which Gross profit 13,273 12,671 +4.8% carry higher margins. Gross margin 53.0% 50.2% +3pps Administrative expenses £9.7m Admin expenses² (9,729)
Slide 16: Adjusted EBITDA
Adjusted EBITDA AEBITDA AEBITDA margin Trend (AEBITDA) Adjusted EBITDA £5.9m Up 2.4% on H1 2025 (£5.8m), and the fourth consecutive year of first-half growth from 6.6 £4.4m in H1 2023. 6.0 5.9 5.9 5.8 Margin 23.6% Gross margin gains outweigh planned opex 5.4 investments in sales and marketing capabi
Slide 17: Investment Focused on Growth
Investment Focused on Growth Opex Capex Commercial leadership Manufacturing capacity senior sales hires in US, Europe, Middle East and 30% expansion of Hemo production line project has Africa. started (c. £4m across 18 months) Product management New sensor production lines (c£2m over 18
Slide 18: ..With a Robust Balance Sheet
..With a Robust Balance Sheet £'000 30 Jun 2026 31 Dec 2025 Intangible assets 28,187 27,884 Non-current assets £50.2m Intangibles include £24m goodwill. Property, plant and equipment¹ 21,947 22,299 £0.9m of PPE additions in H1 (H1 2025: £0.5m) Inventories 9,137 8,302 Trade and other receivables 6,99
Slide 19: Cash Flow
Cash Flow Cash balance bridge (£m) Cash £16.0m (0.8) Including £2.4m held in Russia. (1.7) Strong operating cashflows to support continued +5.9 (1.8) (0.3) (0.9) (0.2) investment in assets 15.8 16.0 Opening AEBITDA Working Tax Capex Leases Buyback Other Closing cap. Free cash flow bridge (£m) Free c
Slide 20: Share Buyback
Share Buyback 23.5m £5.9m 0.54p Shares repurchased since Cash returned to date at an Basic EPS, up 14.9% from launch - 5.2% of opening share average price of 25.2p (inc. 0.47p in H1 2025 capital costs) Shares in issue (m) EPS impact H1 2025 H1 2026 Change 453.7 Weighted average shares (m) 448.3 431.
Slide 21: Summary
Summary Solid H1 Performance Return to Point-of-Care Growth in H2 FY 2026 expected to be in line with expectations Continue to Drive β-HB Expansion Deliver on the Five-Year Strategy 21
Slide 22: Thank You
Thank You Thank You ekfdiagnostics.com MRK-PRES-E-2025-004-EN
Slide 23: Appendix
Appendix 23
Slide 24: EKF Diagnostics at a Glance
Point-of-Care Life Sciences Providing quick and accurate results for Cutting-edge technology with capacity to healthcare professionals to make rapid deliver projects from research to decisions at or near the patient’s location commercial scale production Hematology Precision Fermentation Blood donat
Slide 25: Global Presence
Global Presence Distribution to over 120 countries Germany EKF has two ISO 13485 certified sites in Germany, located in Magdeburg and Leipzig, manufacturing and distributing our Point-of-Care portfolio Texas Our FDA regulated facility in Boerne, Texas manufactures our class-leading β-HB chemistry re
Slide 26: Point-of-Care: Hematology
Point-of-Care: Featured Products Delivering immediate lab-quality results in just one second, DiaSpect Tm Hematology streamlines blood analysis, making it a valuable tool for healthcare screening and testing, DiaSpect Tm is essential for professionals in remote or mobile settings. Hemo Control is a
Slide 27: Point-of-Care: Diabetes
Point-of-Care: Featured Products The easy-to-use Biosen C-Line is a familiar name in laboratories, sports medicine, Diabetes and diabetes clinics, with two models available, the Biosen C-Line Clinic (up to 20 samples) and Biosen C-Line GP+ (up to 5 samples). Providing lab-accurate results in just fo
Slide 28: Point-of-Care: Sports Performance
Point-of-Care: Featured Products Lactate Scout Sport is a reliable lactate analyzer perfect for training outdoors, in Sports the gym, or for analysing performance in a sports lab, Lactate Scout Sport is the number one choice for sports scientists and professional athletes. Performance Lactate Scout
Slide 29: Life Sciences: Portfolio
Life Sciences: Featured Product The Beta-Hydroxybutyrate LiquiColor® reagent is a quantitative, FDA-cleared test Portfolio for detecting ketones and monitoring diabetic ketoacidosis, compatible with open- channel analyzers, it integrates seamlessly into laboratory workflows. Beta-Hydroxybutyrate Liq
Slide 30: Featured Services and Products
Featured Services and Products Precision Fermentation facilities and technologies that scale the fermentation of biomaterials in healthcare, engineered to accommodate the dynamic needs of modern science, setting a benchmark for modernity and efficiency. Custom Bioprocessing technologies and capabili
Slide 31: Disclaimer
Disclaimer The information contained in this presentation and any accompanying oral presentation (together, the “Presentation”) has been prepared by EKF Diagnostics Holdings plc or one of its subsidiary companies (the “Company”). This Presentation is subject to updating, completion, revision, and am
EKF Diagnostics Holdings — H1 2026 Earnings Presentation on 6ix